{"protocolSection": {"identificationModule": {"nctId": "NCT00407537", "orgStudyIdInfo": {"id": "A3841047"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors", "officialTitle": "A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice", "acronym": "CRUCIAL"}, "statusModule": {"statusVerifiedDate": "2021-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-03"}, "primaryCompletionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-12-01", "studyFirstSubmitQcDate": "2006-12-04", "studyFirstPostDateStruct": {"date": "2006-12-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-10-06", "resultsFirstSubmitQcDate": "2011-10-05", "resultsFirstPostDateStruct": {"date": "2011-11-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-01-26", "lastUpdatePostDateStruct": {"date": "2021-01-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors."}, "conditionsModule": {"conditions": ["Hypertension", "Hypercholesterolemia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1531, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Caduet", "type": "EXPERIMENTAL", "description": "Open label caduet added to usual care regimen followed by investigators.", "interventionNames": ["Drug: Amlodipine besylate/atorvastatin calcium single pill combination"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine besylate/atorvastatin calcium single pill combination", "description": "Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion", "armGroupLabels": ["Caduet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12", "description": "Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).", "timeFrame": "Baseline, Month 12"}], "secondaryOutcomes": [{"measure": "Framingham 10-year Risk of Total CHD at Month 4", "description": "Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).", "timeFrame": "Baseline, Month 4"}, {"measure": "European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12", "description": "European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).", "timeFrame": "Baseline, Month 12"}, {"measure": "European SCORE 10-year Risk of Fatal CVD at Month 4", "description": "European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).", "timeFrame": "Baseline, Month 4"}, {"measure": "Framingham 10-year Risk of Stroke at Month 12", "description": "Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific \"calibration factor\" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).", "timeFrame": "Baseline, Month 12"}, {"measure": "Framingham 10-year Risk of Stroke at Month 4", "description": "Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific \"calibration factor\" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).", "timeFrame": "Baseline, Month 4"}, {"measure": "Change From Baseline in Framingham 10-year Risk of Developing Total CHD", "description": "Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.", "timeFrame": "Baseline, Month 4, Month 12"}, {"measure": "Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD", "description": "European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.", "timeFrame": "Baseline, Month 4, Month 12"}, {"measure": "Mean Systolic and Diastolic Blood Pressure at Month 4", "timeFrame": "Month 4"}, {"measure": "Mean Systolic and Diastolic Blood Pressure at Month 12", "timeFrame": "Month 12"}, {"measure": "Change From Baseline in Systolic Blood Pressure (SBP) at Month 4", "timeFrame": "Baseline, Month 4"}, {"measure": "Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4", "timeFrame": "Baseline, Month 4"}, {"measure": "Change From Baseline in SBP at Month 12", "timeFrame": "Baseline, Month 12"}, {"measure": "Change From Baseline in DBP at Month 12", "timeFrame": "Baseline, Month 12"}, {"measure": "Mean Lipid Parameters at Month 4", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.", "timeFrame": "Month 4"}, {"measure": "Mean Lipid Parameters at Month 12", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.", "timeFrame": "Month 12"}, {"measure": "Change From Baseline in Lipid Parameters at Month 4", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.", "timeFrame": "Baseline, Month 4"}, {"measure": "Change From Baseline in Lipid Parameters at Month 12", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.", "timeFrame": "Baseline, Month 12"}, {"measure": "Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months", "description": "Goals set at \\<140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and \\<140/90 mm Hg or \\<130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.", "timeFrame": "Month 4, Month 12"}, {"measure": "Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months", "description": "Goal set at \\<100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at \\<80 mg/dL according to the European (EU) Society of Cardiology guidelines.", "timeFrame": "Month 4, Month 12"}, {"measure": "Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months", "description": "Treatments indicative of prescribed medications other than study provided Caduet.", "timeFrame": "Month 4, Month 12"}, {"measure": "Number of Participants With Increase of Treatment Dosages After 4 Months.", "description": "Treatments indicative of prescribed medications other than study provided Caduet.", "timeFrame": "Month 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Hypertension with three additional risks factors (for example: smoking, type 2 diabetes, family history of early heart disease, history of stroke, age over 55 (men) and 65 (women)\n\nExclusion Criteria:\n\n* Subjects currently receiving a statin or stopped statin within 6 months prior to enrollment.\n* Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "35 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Pfizer Investigational Site", "city": "Desamparados", "state": "San Jose", "country": "Costa Rica", "geoPoint": {"lat": 9.94727, "lon": -84.50626}}, {"facility": "Pfizer Investigational Site", "city": "Heredia", "country": "Costa Rica", "geoPoint": {"lat": 10.00236, "lon": -84.11651}}, {"facility": "Pfizer Investigational Site", "city": "San Jose", "country": "Costa Rica", "geoPoint": {"lat": 9.93333, "lon": -84.08333}}, {"facility": "Pfizer Investigational Site", "city": "Breznicki Hum", "zip": "42225", "country": "Croatia", "geoPoint": {"lat": 46.10722, "lon": 16.27667}}, {"facility": "Pfizer Investigational Site", "city": "Cakovec", "zip": "40000", "country": "Croatia", "geoPoint": {"lat": 46.38444, "lon": 16.43389}}, {"facility": "Pfizer Investigational Site", "city": "Crikvenica", "zip": "51260", "country": "Croatia", "geoPoint": {"lat": 45.17722, "lon": 14.69278}}, {"facility": "Pfizer Investigational Site", "city": "Karlovac", "zip": "47000", "country": "Croatia", "geoPoint": {"lat": 45.48941, "lon": 15.54887}}, {"facility": "Pfizer Investigational Site", "city": "Rijeka", "zip": "51000", "country": "Croatia", "geoPoint": {"lat": 45.32674, "lon": 14.44239}}, {"facility": "Pfizer Investigational Site", "city": "Spisic Bukovica", "zip": "33404", "country": "Croatia", "geoPoint": {"lat": 45.85722, "lon": 17.29944}}, {"facility": "Pfizer Investigational Site", "city": "Split", "zip": "21000", "country": "Croatia", "geoPoint": {"lat": 43.50891, "lon": 16.43915}}, {"facility": "Pfizer Investigational Site", "city": "Sv. Kriz Zacretje", "zip": "49223", "country": "Croatia"}, {"facility": "Pfizer Investigational Site", "city": "Varazdin", "zip": "42000", "country": "Croatia", "geoPoint": {"lat": 46.30444, "lon": 16.33778}}, {"facility": "Pfizer Investigational Site", "city": "Zagreb", "zip": "10000", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "Pfizer Investigational Site", "city": "Brno", "zip": "656 91", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Pfizer Investigational Site", "city": "Klatovy", "zip": "339 01", "country": "Czechia", "geoPoint": {"lat": 49.39552, "lon": 13.29505}}, {"facility": "Pfizer Investigational Site", "city": "Kralupy nad Vltavou", "zip": "278 01", "country": "Czechia", "geoPoint": {"lat": 50.24107, "lon": 14.31149}}, {"facility": "Pfizer Investigational Site", "city": "Lanskroun", "zip": "563 01", "country": "Czechia", "geoPoint": {"lat": 49.91217, "lon": 16.6119}}, {"facility": "Pfizer Investigational Site", "city": "Olomouc", "zip": "779 00", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Pfizer Investigational Site", "city": "Pelhrimov", "zip": "393 01", "country": "Czechia", "geoPoint": {"lat": 49.43134, "lon": 15.22336}}, {"facility": "Pfizer Investigational Site", "city": "Praha 4", "zip": "141 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Pfizer Investigational Site", "city": "Praha 8", "zip": "186 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Pfizer Investigational Site", "city": "Pruhonice", "zip": "252 43", "country": "Czechia", "geoPoint": {"lat": 49.99962, "lon": 14.55017}}, {"facility": "Pfizer Investigational Site", "city": "Usti nad Labem", "zip": "400 07", "country": "Czechia", "geoPoint": {"lat": 50.6607, "lon": 14.03227}}, {"facility": "Pfizer Investigational Site", "city": "Vratimov", "zip": "739 32", "country": "Czechia", "geoPoint": {"lat": 49.76995, "lon": 18.31015}}, {"facility": "Pfizer Investigational Site", "city": "Zlin 4", "zip": "763 02", "country": "Czechia", "geoPoint": {"lat": 49.22645, "lon": 17.67065}}, {"facility": "Pfizer Investigational Site", "city": "San Cristobal", "country": "Dominican Republic", "geoPoint": {"lat": 18.41667, "lon": -70.1}}, {"facility": "Pfizer Investigational Site", "city": "Santo Domingo", "zip": "4966", "country": "Dominican Republic", "geoPoint": {"lat": 18.50012, "lon": -69.98857}}, {"facility": "Pfizer Investigational Site", "city": "Santo Domingo", "country": "Dominican Republic", "geoPoint": {"lat": 18.50012, "lon": -69.98857}}, {"facility": "Pfizer Investigational Site", "city": "Cilandak", "state": "Jakarta Selatan", "zip": "12430", "country": "Indonesia"}, {"facility": "Pfizer Investigational Site", "city": "Bandung", "zip": "40161", "country": "Indonesia", "geoPoint": {"lat": -6.92222, "lon": 107.60694}}, {"facility": "Pfizer Investigational Site", "city": "Jakarta", "zip": "10430", "country": "Indonesia", "geoPoint": {"lat": -6.21462, "lon": 106.84513}}, {"facility": "Pfizer Investigational Site", "city": "Jakarta", "zip": "11420", "country": "Indonesia", "geoPoint": {"lat": -6.21462, "lon": 106.84513}}, {"facility": "Pfizer Investigational Site", "city": "Semarang", "zip": "50231", "country": "Indonesia", "geoPoint": {"lat": -6.99306, "lon": 110.42083}}, {"facility": "Pfizer Investigational Site", "city": "Surabaya", "zip": "60286", "country": "Indonesia", "geoPoint": {"lat": -7.24917, "lon": 112.75083}}, {"facility": "Pfizer Investigational Site", "city": "Tangerang", "zip": "15224", "country": "Indonesia", "geoPoint": {"lat": -6.17806, "lon": 106.63}}, {"facility": "Pfizer Investigational Site", "city": "Tanggerang", "zip": "15811", "country": "Indonesia"}, {"facility": "Pfizer Investigational Site", "city": "Amman", "zip": "11181", "country": "Jordan", "geoPoint": {"lat": 31.95522, "lon": 35.94503}}, {"facility": "Pfizer Investigational Site", "city": "Amman", "zip": "11942", "country": "Jordan", "geoPoint": {"lat": 31.95522, "lon": 35.94503}}, {"facility": "Pfizer Investigational Site", "city": "Irbid", "zip": "22110", "country": "Jordan", "geoPoint": {"lat": 32.55556, "lon": 35.85}}, {"facility": "Pfizer Investigational Site", "city": "Wonju-si", "state": "Gangwon-Do", "zip": "220-701", "country": "Korea, Republic of"}, {"facility": "Pfizer Investigational Site", "city": "Seongnam-si", "state": "Gyeonggi-do", "zip": "463-707", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Pfizer Investigational Site", "city": "Busan", "zip": "602-715", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Pfizer Investigational Site", "city": "Busan", "zip": "614-735", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Pfizer Investigational Site", "city": "Daegu", "zip": "700-712", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Pfizer Investigational Site", "city": "Daegu", "zip": "705-718", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Pfizer Investigational Site", "city": "Daejeon", "zip": "301-721", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Pfizer Investigational Site", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Pfizer Investigational Site", "city": "Incheon", "zip": "405-760", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Pfizer Investigational Site", "city": "Seoul,", "zip": "150-713", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "zip": "110-744", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "zip": "135-710", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "zip": "135-720", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "zip": "136-705", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "zip": "137-040", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "zip": "138-736", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "zip": "152-703", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Pfizer Investigational Site", "city": "Suwon", "zip": "443-721", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Pfizer Investigational Site", "city": "Kuwait", "country": "Kuwait", "geoPoint": {"lat": 29.36972, "lon": 47.97833}}, {"facility": "Pfizer Investigational Site", "city": "Sasat", "zip": "13110", "country": "Kuwait"}, {"facility": "Pfizer Investigational Site", "city": "Beirut", "country": "Lebanon", "geoPoint": {"lat": 33.88894, "lon": 35.49442}}, {"facility": "Pfizer Investigational Site", "city": "Jbeil", "country": "Lebanon"}, {"facility": "Pfizer Investigational Site", "city": "Kuala Pilah", "state": "Negeri Sembilan", "zip": "72000", "country": "Malaysia", "geoPoint": {"lat": 2.7389, "lon": 102.2487}}, {"facility": "Pfizer Investigational Site", "city": "Seremban", "state": "Negeri Sembilan", "zip": "70300", "country": "Malaysia", "geoPoint": {"lat": 2.7297, "lon": 101.9381}}, {"facility": "Pfizer Investigational Site", "city": "Batu Caves", "state": "Selangor", "zip": "68100", "country": "Malaysia", "geoPoint": {"lat": 3.23333, "lon": 101.66667}}, {"facility": "Pfizer Investigational Site", "city": "Petaling Jaya", "state": "Selangor", "zip": "47301", "country": "Malaysia", "geoPoint": {"lat": 3.10726, "lon": 101.60671}}, {"facility": "Pfizer Investigational Site", "city": "Butterworth", "zip": "13000", "country": "Malaysia", "geoPoint": {"lat": 5.3991, "lon": 100.36382}}, {"facility": "Pfizer Investigational Site", "city": "Kuala Lumpur", "zip": "57000", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}, {"facility": "Pfizer Investigational Site", "city": "Kuala Lumpur", "zip": "59100", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}, {"facility": "Pfizer Investigational Site", "city": "Mexico", "state": "DF", "zip": "02720", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Pfizer Investigational Site", "city": "Mexico", "state": "DF", "zip": "07300", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Pfizer Investigational Site", "city": "Mexico", "state": "DF", "zip": "09220", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Pfizer Investigational Site", "city": "Mexico", "state": "DF", "zip": "10700", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Pfizer Investigational Site", "city": "Toluca", "state": "Estado De Mexico", "zip": "50010", "country": "Mexico", "geoPoint": {"lat": 19.28786, "lon": -99.65324}}, {"facility": "Pfizer Investigational Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44200", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Pfizer Investigational Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44340", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Pfizer Investigational Site", "city": "Durango", "zip": "34078", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Pfizer Investigational Site", "city": "San Luis Potosi", "zip": "78200", "country": "Mexico", "geoPoint": {"lat": 22.14982, "lon": -100.97916}}, {"facility": "Pfizer Investigational Site", "city": "Panama City", "country": "Panama", "geoPoint": {"lat": 8.9936, "lon": -79.51973}}, {"facility": "Pfizer Investigational Site", "city": "Panama", "country": "Panama", "geoPoint": {"lat": 8.9936, "lon": -79.51973}}, {"facility": "Pfizer Investigational Site", "city": "San Juan", "state": "Metro Manila", "country": "Philippines", "geoPoint": {"lat": 14.6, "lon": 121.0333}}, {"facility": "Pfizer Investigational Site", "city": "Makati City", "zip": "1218", "country": "Philippines", "geoPoint": {"lat": 14.55027, "lon": 121.03269}}, {"facility": "Pfizer Investigational Site", "city": "Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Pfizer Investigational Site", "city": "Marikina City", "country": "Philippines", "geoPoint": {"lat": 14.6481, "lon": 121.1133}}, {"facility": "Pfizer Investigational Site", "city": "Quezon City", "zip": "1101", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Pfizer Investigational Site", "city": "Moscow", "zip": "101953", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Pfizer Investigational Site", "city": "Moscow", "zip": "1117292", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Pfizer Investigational Site", "city": "Moscow", "zip": "115093", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Pfizer Investigational Site", "city": "Moscow", "zip": "117485", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Pfizer Investigational Site", "city": "Saint Petersburg", "zip": "199106", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Pfizer Investigational Site", "city": "Saint-Petersburg", "zip": "192242", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Pfizer Investigational Site", "city": "Saint-Petersburg", "zip": "196084", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Pfizer Investigational Site", "city": "Smolensk", "zip": "214018", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Pfizer Investigational Site", "city": "St. Petersburg", "zip": "190000", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Pfizer Investigational Site", "city": "St. Petersburg", "zip": "194291", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Pfizer Investigational Site", "city": "St. Petersburg", "zip": "195067", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Pfizer Investigational Site", "city": "Volgograd", "zip": "400008", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Pfizer Investigational Site", "city": "Voronezh", "zip": "394053", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}, {"facility": "Pfizer Investigational Site", "city": "Riyadh 11426", "zip": "Riyadh 11426", "country": "Saudi Arabia", "geoPoint": {"lat": 24.68773, "lon": 46.72185}}, {"facility": "Pfizer Investigational Site", "city": "Kaohsiung", "zip": "807", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Pfizer Investigational Site", "city": "Kaohsiung", "zip": "833", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Pfizer Investigational Site", "city": "Taichung", "zip": "402", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Pfizer Investigational Site", "city": "Taichung", "zip": "407", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Pfizer Investigational Site", "city": "Tainan", "zip": "704", "country": "Taiwan", "geoPoint": {"lat": 22.99083, "lon": 120.21333}}, {"facility": "Pfizer Investigational Site", "city": "Tainan", "zip": "710", "country": "Taiwan", "geoPoint": {"lat": 22.99083, "lon": 120.21333}}, {"facility": "Pfizer Investigational Site", "city": "Taipei", "zip": "100", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Pfizer Investigational Site", "city": "Taipei", "zip": "112", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Pfizer Investigational Site", "city": "Taipei", "zip": "231", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Pfizer Investigational Site", "city": "Rajthevee", "state": "Bangkok", "zip": "10400", "country": "Thailand"}, {"facility": "Pfizer Investigational Site", "city": "Saimai", "state": "Bangkok", "zip": "10220", "country": "Thailand"}, {"facility": "Pfizer Investigational Site", "city": "Bangkok", "zip": "10330", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Pfizer Investigational Site", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Pfizer Investigational Site", "city": "Ankara", "zip": "06600", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Pfizer Investigational Site", "city": "Istanbul", "zip": "34087", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Pfizer Investigational Site", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Pfizer Investigational Site", "city": "Istanbul", "zip": "34296", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Pfizer Investigational Site", "city": "Istanbul", "zip": "34390", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Pfizer Investigational Site", "city": "Izmir", "zip": "35340", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Pfizer Investigational Site", "city": "Izmir", "zip": "35360", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Pfizer Investigational Site", "city": "Abu Dhabi", "country": "United Arab Emirates", "geoPoint": {"lat": 24.46667, "lon": 54.36667}}, {"facility": "Pfizer Investigational Site", "city": "Al Ain", "country": "United Arab Emirates", "geoPoint": {"lat": 24.19167, "lon": 55.76056}}, {"facility": "Pfizer Investigational Site", "city": "Dubai", "country": "United Arab Emirates", "geoPoint": {"lat": 25.0657, "lon": 55.17128}}, {"facility": "Pfizer Investigational Site", "city": "Naguanagua/Valencia", "state": "Carabobo", "zip": "2001", "country": "Venezuela"}, {"facility": "Pfizer Investigational Site", "city": "Caracas", "state": "Dtto Capital/Municipio Libertador", "zip": "1050", "country": "Venezuela", "geoPoint": {"lat": 10.48801, "lon": -66.87919}}, {"facility": "Pfizer Investigational Site", "city": "Caracas", "state": "Dtto Capital/Municipio Libertador", "zip": "1053", "country": "Venezuela", "geoPoint": {"lat": 10.48801, "lon": -66.87919}}, {"facility": "Pfizer Investigational Site", "city": "Valencia", "state": "Estado Carabobo", "zip": "2001", "country": "Venezuela", "geoPoint": {"lat": 10.16202, "lon": -68.00765}}]}, "referencesModule": {"references": [{"pmid": "24339703", "type": "DERIVED", "citation": "Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M; CRUCIAL Trial Investigators. Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific Asian patients participating in the CRUCIAL trial. J Korean Med Sci. 2013 Dec;28(12):1741-8. doi: 10.3346/jkms.2013.28.12.1741. Epub 2013 Nov 26."}, {"pmid": "23464930", "type": "DERIVED", "citation": "Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Curr Med Res Opin. 2013 Jun;29(6):589-96. doi: 10.1185/03007995.2013.783795. Epub 2013 Apr 3."}, {"pmid": "22913893", "type": "DERIVED", "citation": "Kim JH, Zamorano J, Erdine S, Pavia A, Al-Khadra A, Sutradhar S, Yunis C; CR UCIAL Investigators. Proactive cardiovascular risk management versus usual care in patients with and without diabetes mellitus: CRUCIAL trial subanalysis. Postgrad Med. 2012 Jul;124(4):41-53. doi: 10.3810/pgm.2012.07.2565."}, {"pmid": "21306285", "type": "DERIVED", "citation": "Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M, Sutradhar S, Yunis C; CRUCIAL Investigators. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011 Apr;27(4):821-33. doi: 10.1185/03007995.2011.555754. Epub 2011 Feb 10."}], "seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3841047&StudyName=Caduet%20vs%20Usual%20Care%20in%20Subjects%20with%20Hypertension%20and%20Additional%20Risk%20Factors"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Prior to group assignment of investigators (who were the unit of randomization), participants were consented and screened for enrollment eligibility; participant selection for enrollment took place before investigator assignment. A total of 1,531 participants were enrolled and attended baseline visit; 1,461 participants received treatment.", "recruitmentDetails": "This was a cluster randomized study: the unit of randomization was the investigator, ie, participants were screened before the investigator was randomized. A total of 136 sites were cluster randomized.", "groups": [{"id": "FG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "FG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "779"}, {"groupId": "FG001", "comment": "4 participants assigned to Caduet treatment received usual care only during the study", "numSubjects": "682"}]}, {"type": "Eligible for Efficacy Analysis", "achievements": [{"groupId": "FG000", "numSubjects": "760"}, {"groupId": "FG001", "numSubjects": "657"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "686"}, {"groupId": "FG001", "numSubjects": "638"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "93"}, {"groupId": "FG001", "numSubjects": "44"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "16"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Caduet as Assigned", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "BG001", "title": "Usual Care as Assigned", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "783"}, {"groupId": "BG001", "value": "678"}, {"groupId": "BG002", "value": "1461"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "18 to 44 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "58"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "113"}]}]}, {"title": "45 to 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "450"}, {"groupId": "BG001", "value": "361"}, {"groupId": "BG002", "value": "811"}]}]}, {"title": "> = 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "275"}, {"groupId": "BG001", "value": "262"}, {"groupId": "BG002", "value": "537"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "368"}, {"groupId": "BG001", "value": "334"}, {"groupId": "BG002", "value": "702"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "415"}, {"groupId": "BG001", "value": "344"}, {"groupId": "BG002", "value": "759"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12", "description": "Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).", "populationDescription": "Full Analysis Set (FAS) included all subjects, in either treatment group, who had blood pressure and lipid data from at least 1 follow-up visit. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "748"}, {"groupId": "OG001", "value": "655"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.5", "spread": "8.26"}, {"groupId": "OG001", "value": "16.3", "spread": "10.51"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "It was estimated that each study site would on average complete 8 evaluable participants, therefore enrolling 164 sites, 1968 participants would provide at least 90% power to detect a 10% relative reduction in the 10-year predicted risk of total CHD at 12 months (as calculated from the Framingham model) from the control arm based on a two-sided t-test with a 5% significance level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "LSMean difference", "paramValue": "-4.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.55", "ciUpperLimit": "-3.89", "estimateComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site."}]}, {"type": "SECONDARY", "title": "Framingham 10-year Risk of Total CHD at Month 4", "description": "Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "745"}, {"groupId": "OG001", "value": "637"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.5", "spread": "7.96"}, {"groupId": "OG001", "value": "16.3", "spread": "10.80"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "LSMean difference", "paramValue": "-4.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.58", "ciUpperLimit": "-3.93", "estimateComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site."}]}, {"type": "SECONDARY", "title": "European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12", "description": "European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "748"}, {"groupId": "OG001", "value": "655"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "2.89"}, {"groupId": "OG001", "value": "3.7", "spread": "3.69"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "LSMean difference", "paramValue": "-0.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.23", "ciUpperLimit": "-0.72", "estimateComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site."}]}, {"type": "SECONDARY", "title": "European SCORE 10-year Risk of Fatal CVD at Month 4", "description": "European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "745"}, {"groupId": "OG001", "value": "637"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "spread": "3.13"}, {"groupId": "OG001", "value": "3.7", "spread": "3.69"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "LSMean difference", "paramValue": "-0.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.16", "ciUpperLimit": "-0.59", "estimateComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site."}]}, {"type": "SECONDARY", "title": "Framingham 10-year Risk of Stroke at Month 12", "description": "Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific \"calibration factor\" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "748"}, {"groupId": "OG001", "value": "655"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.7", "spread": "2.25"}, {"groupId": "OG001", "value": "4.9", "spread": "2.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "LSMean difference", "paramValue": "-1.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.56", "ciUpperLimit": "-1.15", "estimateComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site."}]}, {"type": "SECONDARY", "title": "Framingham 10-year Risk of Stroke at Month 4", "description": "Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific \"calibration factor\" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "745"}, {"groupId": "OG001", "value": "637"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.7", "spread": "2.21"}, {"groupId": "OG001", "value": "4.9", "spread": "2.81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "LSMean difference", "paramValue": "-1.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.57", "ciUpperLimit": "-1.14", "estimateComment": "Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Framingham 10-year Risk of Developing Total CHD", "description": "Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 4, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "Month 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.2705", "lowerLimit": "-7.90", "upperLimit": "-6.64"}, {"groupId": "OG001", "value": "-2.5155", "lowerLimit": "-3.19", "upperLimit": "-1.84"}]}]}, {"title": "Month 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.2374", "lowerLimit": "-7.87", "upperLimit": "-6.61"}, {"groupId": "OG001", "value": "-2.5167", "lowerLimit": "-3.19", "upperLimit": "-1.84"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD", "description": "European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent risk", "timeFrame": "Baseline, Month 4, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "748"}, {"groupId": "OG001", "value": "655"}]}], "classes": [{"title": "Month 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8438", "lowerLimit": "-2.06", "upperLimit": "-1.63"}, {"groupId": "OG001", "value": "-0.9678", "lowerLimit": "-1.20", "upperLimit": "-0.74"}]}]}, {"title": "Month 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9693", "lowerLimit": "-2.16", "upperLimit": "-1.77"}, {"groupId": "OG001", "value": "-0.9963", "lowerLimit": "-1.21", "upperLimit": "-0.79"}]}]}]}, {"type": "SECONDARY", "title": "Mean Systolic and Diastolic Blood Pressure at Month 4", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "759"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "Systolic", "categories": [{"measurements": [{"groupId": "OG000", "value": "133.5", "spread": "14.32"}, {"groupId": "OG001", "value": "134.5", "spread": "14.96"}]}]}, {"title": "Diastolic", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.7", "spread": "8.74"}, {"groupId": "OG001", "value": "81.1", "spread": "9.32"}]}]}]}, {"type": "SECONDARY", "title": "Mean Systolic and Diastolic Blood Pressure at Month 12", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "Systolic", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.6", "spread": "13.84"}, {"groupId": "OG001", "value": "134.3", "spread": "15.21"}]}]}, {"title": "Diastolic", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.2", "spread": "8.39"}, {"groupId": "OG001", "value": "81.1", "spread": "9.27"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure (SBP) at Month 4", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHG", "timeFrame": "Baseline, Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "759"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.3088", "lowerLimit": "-17.02", "upperLimit": "-13.60"}, {"groupId": "OG001", "value": "-12.1619", "lowerLimit": "-14.00", "upperLimit": "-10.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.007", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.42", "ciUpperLimit": "-0.88"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHG", "timeFrame": "Baseline, Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "759"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.3024", "lowerLimit": "-9.24", "upperLimit": "-7.36"}, {"groupId": "OG001", "value": "-6.6908", "lowerLimit": "-7.70", "upperLimit": "-5.68"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.011", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.86", "ciUpperLimit": "-0.37"}]}, {"type": "SECONDARY", "title": "Change From Baseline in SBP at Month 12", "populationDescription": "FAS, number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.2409", "lowerLimit": "-19.94", "upperLimit": "-16.55"}, {"groupId": "OG001", "value": "-12.4903", "lowerLimit": "-14.32", "upperLimit": "-10.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.00", "ciUpperLimit": "-3.50"}]}, {"type": "SECONDARY", "title": "Change From Baseline in DBP at Month 12", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing to data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.0128", "lowerLimit": "-10.96", "upperLimit": "-9.07"}, {"groupId": "OG001", "value": "-6.8429", "lowerLimit": "-7.86", "upperLimit": "-5.83"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.42", "ciUpperLimit": "-1.92"}]}, {"type": "SECONDARY", "title": "Mean Lipid Parameters at Month 4", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "TC", "categories": [{"measurements": [{"groupId": "OG000", "value": "156.0", "spread": "34.14"}, {"groupId": "OG001", "value": "195.2", "spread": "37.03"}]}]}, {"title": "LDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.9", "spread": "28.47"}, {"groupId": "OG001", "value": "116.4", "spread": "32.47"}]}]}, {"title": "HDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.6", "spread": "13.93"}, {"groupId": "OG001", "value": "46.8", "spread": "13.49"}]}]}, {"title": "Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "143.5", "spread": "83.26"}, {"groupId": "OG001", "value": "164.8", "spread": "95.74"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "TC", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-38.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-43.71", "ciUpperLimit": "-34.17"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "LDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-35.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.64", "ciUpperLimit": "-30.99"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "HDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.087", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.14", "ciUpperLimit": "2.13"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Triglycerides", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effects linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-23.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.60", "ciUpperLimit": "-14.70"}]}, {"type": "SECONDARY", "title": "Mean Lipid Parameters at Month 12", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "TC", "categories": [{"measurements": [{"groupId": "OG000", "value": "163.3", "spread": "38.42"}, {"groupId": "OG001", "value": "196.6", "spread": "36.36"}]}]}, {"title": "LDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.1", "spread": "32.40"}, {"groupId": "OG001", "value": "117.3", "spread": "31.57"}]}]}, {"title": "HDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.3", "spread": "13.48"}, {"groupId": "OG001", "value": "47.1", "spread": "13.61"}]}]}, {"title": "Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "151.5", "spread": "98.61"}, {"groupId": "OG001", "value": "166.4", "spread": "98.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "TC", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-33.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-37.57", "ciUpperLimit": "-28.56"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "LDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-29.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.70", "ciUpperLimit": "-25.95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "HDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.379", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "0.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.71", "ciUpperLimit": "1.86"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Triglycerides", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.72", "ciUpperLimit": "-7.81"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Lipid Parameters at Month 4", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "752"}, {"groupId": "OG001", "value": "630"}]}], "classes": [{"title": "TC", "categories": [{"measurements": [{"groupId": "OG000", "value": "-42.7542", "lowerLimit": "-46.35", "upperLimit": "-39.15"}, {"groupId": "OG001", "value": "-3.8144", "lowerLimit": "-7.75", "upperLimit": "0.12"}]}]}, {"title": "LDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "-38.2765", "lowerLimit": "-41.52", "upperLimit": "-35.03"}, {"groupId": "OG001", "value": "-2.9628", "lowerLimit": "-6.50", "upperLimit": "0.58"}]}]}, {"title": "HDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2060", "lowerLimit": "-1.07", "upperLimit": "0.65"}, {"groupId": "OG001", "value": "-1.1978", "lowerLimit": "-2.13", "upperLimit": "-0.26"}]}]}, {"title": "Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.5645", "lowerLimit": "-27.30", "upperLimit": "-13.83"}, {"groupId": "OG001", "value": "3.0828", "lowerLimit": "-4.26", "upperLimit": "10.43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "TC", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-38.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-43.71", "ciUpperLimit": "-34.17"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "LDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-35.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.64", "ciUpperLimit": "-30.99"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "HDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.087", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.14", "ciUpperLimit": "2.13"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Triglycerides", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-23.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.60", "ciUpperLimit": "-14.70"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Lipid Parameters at Month 12", "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "TC", "categories": [{"measurements": [{"groupId": "OG000", "value": "-37.1024", "lowerLimit": "-40.52", "upperLimit": "-33.69"}, {"groupId": "OG001", "value": "-4.0368", "lowerLimit": "-7.71", "upperLimit": "-0.36"}]}]}, {"title": "LDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "-33.2420", "lowerLimit": "-36.17", "upperLimit": "-30.32"}, {"groupId": "OG001", "value": "-3.4168", "lowerLimit": "-6.58", "upperLimit": "-0.25"}]}]}, {"title": "HDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4339", "lowerLimit": "-1.41", "upperLimit": "0.54"}, {"groupId": "OG001", "value": "-1.0105", "lowerLimit": "-2.06", "upperLimit": "0.04"}]}]}, {"title": "Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.2270", "lowerLimit": "-23.12", "upperLimit": "-7.33"}, {"groupId": "OG001", "value": "3.0398", "lowerLimit": "-5.51", "upperLimit": "11.59"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Total cholesterol", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-33.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-37.57", "ciUpperLimit": "-28.56"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "LDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-29.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.70", "ciUpperLimit": "-25.95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "HDL", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.379", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "0.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.71", "ciUpperLimit": "1.86"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Triglycerides", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.", "statisticalMethod": "Mixed-effect linear model", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.72", "ciUpperLimit": "-7.81"}]}, {"type": "SECONDARY", "title": "Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months", "description": "Goals set at \\<140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and \\<140/90 mm Hg or \\<130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Month 4, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "JNC Month 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.2"}, {"groupId": "OG001", "value": "62.6"}]}]}, {"title": "JNC Month 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.1"}, {"groupId": "OG001", "value": "60.6"}]}]}, {"title": "ESC Month 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.6"}, {"groupId": "OG001", "value": "46.0"}]}]}, {"title": "ESC Month 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.2"}, {"groupId": "OG001", "value": "47.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months", "description": "Goal set at \\<100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at \\<80 mg/dL according to the European (EU) Society of Cardiology guidelines.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Month 4, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "US Month 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.3"}, {"groupId": "OG001", "value": "28.2"}]}]}, {"title": "US Month 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.9"}, {"groupId": "OG001", "value": "28.8"}]}]}, {"title": "EU Month 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.4"}, {"groupId": "OG001", "value": "13.3"}]}]}, {"title": "EU Month 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "46.7"}, {"groupId": "OG001", "value": "11.5"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months", "description": "Treatments indicative of prescribed medications other than study provided Caduet.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Month 4, Month 12", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "Month 4: anti-hypertensive and/or lipid lowering", "categories": [{"measurements": [{"groupId": "OG000", "value": "648"}, {"groupId": "OG001", "value": "642"}]}]}, {"title": "Month 4: anti-hypertensive", "categories": [{"measurements": [{"groupId": "OG000", "value": "647"}, {"groupId": "OG001", "value": "637"}]}]}, {"title": "Month 4: lipid lowering", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "202"}]}]}, {"title": "Month 4: anti-hypertensive and lipid lowering", "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "197"}]}]}, {"title": "Month 12: anti-hypertensive and/or lipid lowering", "categories": [{"measurements": [{"groupId": "OG000", "value": "655"}, {"groupId": "OG001", "value": "642"}]}]}, {"title": "Month 12: anti-hypertensive", "categories": [{"measurements": [{"groupId": "OG000", "value": "654"}, {"groupId": "OG001", "value": "638"}]}]}, {"title": "Month 12: lipid lowering", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "208"}]}]}, {"title": "Month 12: anti-hypertensive and lipid lowering", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "204"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Increase of Treatment Dosages After 4 Months.", "description": "Treatments indicative of prescribed medications other than study provided Caduet.", "populationDescription": "FAS. Number of participants analyzed refers to number of participants contributing data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Month 4", "groups": [{"id": "OG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion."}, {"id": "OG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "760"}, {"groupId": "OG001", "value": "657"}]}], "classes": [{"title": "Increased dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "90"}]}]}, {"title": "increased dose of anti-hypertensive medications", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "88"}]}]}, {"title": "increased dose of lipid lowering medications", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "increase in either medication", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "45"}]}]}, {"title": "increase in both medications", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.", "eventGroups": [{"id": "EG000", "title": "Caduet", "description": "Open label amlodipine besylate/atorvastatin calcium (Caduet) single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion.", "seriousNumAffected": 51, "seriousNumAtRisk": 779, "otherNumAffected": 356, "otherNumAtRisk": 779}, {"id": "EG001", "title": "Usual Care", "description": "Full choice of any locally approved (and not contra indicated) anti-hypertensive and/or lipid lowering drugs, including, but not limited to amlodipine and atorvastatin, according to local clinical practice.", "seriousNumAffected": 22, "seriousNumAtRisk": 682, "otherNumAffected": 289, "otherNumAtRisk": 682}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Macular hole", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Normal tension glaucoma", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Vitreous haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Dysphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Biliary colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Cholestasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Jaundice", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Arthritis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Fractured coccyx", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Electrocardiogram T wave inversion", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Adrenal adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Lipoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Metastases to liver", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Metastases to peritoneum", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Non-Hodgkin's lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cerebellar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cerebrovascular disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Facial palsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hemiparesis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Thrombotic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Upper motor neurone lesion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Panic attack", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Choluria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Renal cyst", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Renal disorder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Renal mass", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Endometriosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Prostatitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Lymphadenitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Normochromic normocytic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Bradyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Left ventricular hypertrophy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 682}]}, {"term": "Supraventricular tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Corneal dystrophy", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Deafness unilateral", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Hearing impaired", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hypoacusis", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Inner ear disorder", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Otosclerosis", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Tinnitus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Vertigo positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Thyroid cyst", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Thyroid mass", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Abnormal sensation in eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Chalazion", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Diabetic retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Iridocyclitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Iritis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Keratitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Macular hole", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Posterior capsule opacification", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Refraction disorder", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Retinal vein occlusion", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Trichiasis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Visual impairment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 682}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Colonic polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Diabetic enteropathy", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 682}]}, {"term": "Epigastric discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Gastric ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 682}]}, {"term": "Gastritis erosive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Gastrointestinal disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Gingival erythema", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Gingival hyperplasia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Gingival swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Glossodynia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Irritable bowel syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Lip swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Mouth ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Oedema mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Peptic ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Periodontitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Rectal polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Reflux oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 682}]}, {"term": "Drug ineffective", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Face oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Generalised oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Impaired healing", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 52, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 682}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tenderness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Thirst", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Biliary colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Hepatic steatosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Allergy to arthropod sting", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 682}]}, {"term": "Bacterial infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Borrelia infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 682}]}, {"term": "Bronchitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Campylobacter intestinal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Catheter site infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Conjunctivitis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Eczema infected", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Folliculitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Fungal skin infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Gingival infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hepatitis B", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Labyrinthitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Localised infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 682}]}, {"term": "Onychomycosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Paronychia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Peritonsillar abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 682}]}, {"term": "Pharyngotonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Pulpitis dental", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Rash pustular", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 682}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Sinusitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Skin candida", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Skin infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tinea pedis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tracheitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Tracheobronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 682}]}, {"term": "Urethritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 682}]}, {"term": "Urogenital infection fungal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Vaginal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Brain contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Eye injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Foreign body trauma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Joint sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Medication error", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Muscle injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Nerve root injury cervical", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tooth injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Alanine aminotransferase decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Blood albumin decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Blood alkaline phosphatase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Blood calcium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Blood calcium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Blood cholesterol increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Blood creatine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 682}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Blood glucose decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Blood potassium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Blood pressure abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Blood triglycerides increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 682}]}, {"term": "Blood urea increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Blood uric acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "ECG signs of myocardial ischaemia", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Glycosylated haemoglobin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Heart rate irregular", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "High density lipoprotein increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Lipids increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Platelet aggregation increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Weight decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 682}]}, {"term": "Food intolerance", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Glucose tolerance impaired", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Hypercalcaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Hypercholesterolaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 682}]}, {"term": "Hypercreatininaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 682}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 682}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 682}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Hypo HDL cholesterolaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hypocalcaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 682}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 682}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 682}]}, {"term": "Bone disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Crystal arthropathy", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Exostosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Flank pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Groin pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Monarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Muscle contracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Muscle haemorrhage", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 682}]}, {"term": "Myositis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 682}]}, {"term": "Osteochondrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 682}]}, {"term": "Osteoporosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 682}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Plantar fasciitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Polyarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Rheumatoid arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Senile osteoporosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Sympathetic posterior cervical syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Temporomandibular joint syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Lipoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Balance disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Carotid arteriosclerosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Carpal tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Cerebral atrophy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cervicobrachial syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dementia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Diabetic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 682}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Head discomfort", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 682}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Nerve root lesion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Neuropathy peripheral", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Restless legs syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tension headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 682}]}, {"term": "Bruxism", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 682}]}, {"term": "Neurosis", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Tic", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Calculus bladder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cystitis haemorrhagic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Nocturia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Renal cyst", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Renal disorder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Renal failure chronic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Atrophic vulvovaginitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Endometrial hypertrophy", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Erectile dysfunction", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Pelvic pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Prostatomegaly", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Vaginal haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Bronchial hyperreactivity", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 682}]}, {"term": "Diaphragmatic hernia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Dyspnoea exertional", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Hypoxia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Oropharyngeal discomfort", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Paranasal cyst", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Respiratory disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Tonsillar inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Upper airway obstruction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Vocal cord polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Alopecia", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Dermatitis atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Dermatosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Neurodermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Pruritus allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Psoriasis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Rash papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Seborrhoeic dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Skin hypopigmentation", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Cataract operation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Circumcision", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Intraocular lens implant", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Lipoma excision", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 682}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 682}]}, {"term": "Intermittent claudication", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Labile blood pressure", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Peripheral ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 682}]}, {"term": "Thrombophlebitis superficial", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 682}]}, {"term": "Venous insufficiency", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 779}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 682}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000006937", "term": "Hypercholesterolemia"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006949", "term": "Hyperlipidemias"}, {"id": "D000050171", "term": "Dyslipidemias"}, {"id": "D000052439", "term": "Lipid Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M9988", "name": "Hypercholesterolemia", "asFound": "Hypercholesterolemia", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M10000", "name": "Hyperlipidemias", "relevance": "LOW"}, {"id": "M10002", "name": "Hyperlipoproteinemias", "relevance": "LOW"}, {"id": "M26181", "name": "Dyslipidemias", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M27029", "name": "Lipid Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000069059", "term": "Atorvastatin"}, {"id": "D000002118", "term": "Calcium"}], "ancestors": [{"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M5381", "name": "Calcium", "asFound": "Double-blind", "relevance": "HIGH"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M351", "name": "Atorvastatin", "asFound": "Analgesic Effect", "relevance": "HIGH"}, {"id": "M19600", "name": "Amlodipine", "asFound": "Valproic Acid", "relevance": "HIGH"}, {"id": "M223699", "name": "Amlodipine, atorvastatin drug combination", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}